Brandes Investment Partners LP Acquires 193,064 Shares of Organon & Co. $OGN

Brandes Investment Partners LP boosted its stake in Organon & Co. (NYSE:OGN) by 46.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 606,499 shares of the company’s stock after buying an additional 193,064 shares during the period. Brandes Investment Partners LP’s holdings in Organon & Co. were worth $4,349,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Foster Dykema Cabot & Partners LLC purchased a new stake in Organon & Co. in the third quarter worth $29,000. Farther Finance Advisors LLC grew its stake in Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares during the period. Rothschild Investment LLC grew its stake in Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in Organon & Co. in the fourth quarter worth $44,000. Finally, Smartleaf Asset Management LLC grew its stake in Organon & Co. by 70.2% in the third quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company’s stock worth $53,000 after purchasing an additional 2,109 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OGN. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Barclays boosted their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Performance

NYSE:OGN opened at $13.38 on Thursday. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.48. The stock has a 50-day moving average price of $11.32 and a 200 day moving average price of $8.81. The stock has a market capitalization of $3.51 billion, a P/E ratio of 14.38, a P/E/G ratio of 1.24 and a beta of 1.55.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 EPS. Equities research analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, May 11th. Organon & Co.’s dividend payout ratio (DPR) is presently 8.60%.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur purchased 26,448 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were acquired at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares of the company’s stock, valued at $705,560.85. The trade was a 100.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.62% of the stock is owned by insiders.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.